A detailed history of Globeflex Capital L P transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Globeflex Capital L P holds 452,606 shares of PBYI stock, worth $1.35 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
452,606
Previous 452,606 -0.0%
Holding current value
$1.35 Million
Previous $1.48 Million 21.76%
% of portfolio
0.11%
Previous 0.16%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.92 - $5.83 $114,303 - $228,215
-39,145 Reduced 7.96%
452,606 $1.48 Million
Q1 2024

May 14, 2024

SELL
$4.29 - $7.4 $200,806 - $346,379
-46,808 Reduced 8.69%
491,751 $2.61 Million
Q3 2023

Nov 13, 2023

SELL
$2.63 - $4.09 $60,413 - $93,951
-22,971 Reduced 4.09%
538,559 $1.42 Million
Q4 2022

Feb 10, 2023

SELL
$2.12 - $5.08 $19,737 - $47,294
-9,310 Reduced 1.63%
561,530 $2.38 Million
Q3 2022

Nov 14, 2022

BUY
$2.27 - $3.84 $343,945 - $581,829
151,518 Added 36.13%
570,840 $1.35 Million
Q2 2022

Aug 15, 2022

BUY
$1.64 - $3.3 $113,320 - $228,023
69,098 Added 19.73%
419,322 $1.2 Million
Q1 2022

May 13, 2022

SELL
$2.13 - $3.24 $134,524 - $204,628
-63,157 Reduced 15.28%
350,224 $1.01 Million
Q4 2021

Feb 10, 2022

SELL
$2.85 - $6.58 $886 - $2,046
-311 Reduced 0.08%
413,381 $1.26 Million
Q3 2021

Nov 12, 2021

SELL
$6.63 - $9.39 $225,479 - $319,344
-34,009 Reduced 7.6%
413,692 $2.9 Million
Q2 2021

Aug 12, 2021

BUY
$8.98 - $11.6 $170,808 - $220,643
19,021 Added 4.44%
447,701 $4.11 Million
Q1 2021

May 14, 2021

BUY
$9.38 - $13.63 $3.5 Million - $5.09 Million
373,653 Added 679.04%
428,680 $4.17 Million
Q3 2020

Nov 13, 2020

SELL
$9.5 - $11.14 $77,890 - $91,336
-8,199 Reduced 12.97%
55,027 $555,000
Q2 2020

Aug 12, 2020

BUY
$7.01 - $13.24 $443,214 - $837,112
63,226 New
63,226 $659,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $136M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Globeflex Capital L P Portfolio

Follow Globeflex Capital L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Globeflex Capital L P, based on Form 13F filings with the SEC.

News

Stay updated on Globeflex Capital L P with notifications on news.